A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
No drugs in Canadian market are affected by the Aurobindo Pharma recall, a Health Canada spokesperson told Global News.
WATCH BELOW: Several blood pressure medications recalled in 2018
The FDA said it will continue to investigate and test all angiotensin II receptor blockers for the presence of NDEA and another probable carcinogen N-nitrosodimethylamine.In October last year, the FDA halted imports of drug ingredients or medicines containing ingredients produced at a factory of a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
© 2019 Reuters
Trending
-
Canada Post says ‘significant’ backlog will be cleared before Christmas3578 Read
-
Ontario Liberal MPs call for Trudeau to step aside: ‘Time is of the essence’2577 Read
-
Ex-OpenAI engineer who raised legal concerns about the technology he helped build has died2342 Read
-
Donald Trump threatens to try and take back the Panama Canal1945 Read
-
Here’s what’s selling for Amazon’s Boxing Day1293 Read
-
‘Vast majority’ of Liberal caucus wants Trudeau to resign, MP says1138 Read
You are viewing an Accelerated Mobile Webpage.
View Original Article